Workflow
玻尿酸女王反腐的真正目的
Bloomage BiotechBloomage Biotech(SH:688363) 虎嗅APP·2025-04-01 00:07

Core Viewpoint - The article discusses the internal turmoil and strategic challenges faced by Huaxi Biological, particularly in light of its declining performance and the need for significant internal reforms to address corruption and strategic misalignment [3][4][5]. Group 1: Internal Challenges and Strategic Issues - Huaxi Biological's CEO Zhao Yan issued an ultimatum for employees involved in corruption to resign by March 31, indicating a critical need for internal restructuring [3]. - The company is experiencing a significant decline in revenue and profits, with a reported drop of over 70% in profits for 2024, highlighting the urgency of the situation [3][4]. - The internal issues are compounded by strategic missteps, particularly the failure to adapt to market changes and the overproduction of hyaluronic acid, leading to an oversupply situation [9][15]. Group 2: Market Dynamics and Competitive Landscape - The hyaluronic acid market has shifted from a scarcity to an oversupply, with average prices dropping from 210 RMB per gram in 2017 to 124 RMB in 2021, a decline of 41% [9]. - New competitors in the collagen market have emerged, capturing consumer interest and market share, which has further pressured Huaxi Biological's traditional hyaluronic acid business [11][12]. - The company has been slow to diversify into collagen products, missing out on a significant market opportunity that could have alleviated current pressures [12][15]. Group 3: Financial Performance and Cost Management - Huaxi Biological's sales and management expenses have surged from 38.23% in 2018 to 61.72% in 2023, with sales expenses alone increasing from 284 million RMB to 2.842 billion RMB during the same period [27]. - Despite maintaining a high gross margin of around 73%, the net profit margin has plummeted from 33.56% in 2018 to approximately 9.27% in 2024, indicating severe profitability issues [27][28]. - The company's strategy to cut costs and improve profitability through internal reforms may provide short-term relief, but long-term success will depend on genuine operational improvements [29][30].